Icosapent ethyl for the treatment of severe hypertriglyceridemia

Figures & data

Table 1 Packaging and transport of triglycerides

Lipoprotein	Triglyceride content (%)
Chylomicrons	85–90
Very low-density lipoproteins	50–60
Intermediate-density lipoproteins	20–25
Low-density lipoprotein	≤10
High-density lipoprotein	≤10

Notes: Triglycerides are transported in various lipoproteins. Chylomicrons and very low-density lipoproteins are the two main lipoprotein transporters for triglycerides.

Figure 1 Mechanism of action of PUFAs in lowering the hepatic production of TGs.

Abbreviations: PUFAs, polyunsaturated fatty acids; PPAR, peroxisome proliferator-activated receptor; TG, triglyceride; FA, fatty acid; VLDL, very low-density lipoprotein.

Figure 2 Results of the MARINE trial.

Note: Data from Jacobson.²⁸
Abbreviations: TG, triglyceride; VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; EPA, eicosapentaenoic acid; MARINE, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-week study with an open-label Extension.

Figure 3 Results of the ANCHOR trial.

Note: Data from Ballantyne et al.⁷
Abbreviations: TG, triglyceride; LDL, low-density lipoprotein; EPA, eicosapentaenoic acid; ANCHOR, Effect of AMR101 (Ethyl Icosapentate) on TG levels in patients on statins with high TG levels (>200 and < 500 mg/dL).

Figure 4 Effects of EPA versus DHA on lipid parameters.

Abbreviations: TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.

JacobsonTAA new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trialExpert Rev Cardiovasc Ther201210668769522894624

 PubMedGoogle Scholar

BallantyneCMBaysHEKasteleinJJEfficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)Am J Cardiol2012110798499222819432

 PubMed Web of Science ®Google Scholar